Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,849.72
+20.001.09%
Number of Gainers:13
Number of Losers:5
Number of Flat:1
PE:- -
High:1,868.25
Open:1,832.45
Low:1,832.45
Close:1,829.73
Volume:15.78M
Turnover:1.01B
Market Cap:1.50T
Float Cap:1.47T

Loading ...

U.S. Earnings Preview: After Market Close Sept. 9

Dow Jones
·
Sep 10

Opus Genetics price target raised to $16 from $13 at Chardan

TIPRANKS
·
Sep 10

TwoStep Therapeutics Raises $62.5 Million in Series a Led by Insight Partners, Medical Excellence Capital

Reuters
·
Sep 10

Moderna Set for 3 Near-Term INT Data Readouts, UBS Says

MT Newswires Live
·
Sep 09

AstraZeneca Shares Look Set for Swift Recovery

Dow Jones
·
Sep 09

AstraZeneca's COPD Drug Data to Boost Sales Outlook

Dow Jones
·
Sep 09

RBC Initiates AstraZeneca at Outperform With GBP145 Price Target

MT Newswires Live
·
Sep 09

BMO Capital Adjusts Price Target on Pfizer to $35 From $30, Keeps Outperform Rating

MT Newswires Live
·
Sep 09

Ocugen to Share Ophthalmic Gene Therapy Progress

TIPRANKS
·
Sep 09

NYSE Most Active Issues

Dow Jones
·
Sep 09

Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program with Gilead

Dow Jones
·
Sep 09

Pfizer Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

Abbott Laboratories Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

BioNTech CEO Ugur Sahin Sells Ordinary Shares Worth $7.86 Million

Reuters
·
Sep 09

Assembly Bio Highlights Phase 2 Starts for ABI-6250, GS-1179 in Pipeline Update

Reuters
·
Sep 09

Assembly Biosciences - Assembly Bio Eligible for up to $280 Mln in Milestones and Royalties Outside U.S.

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gs-1179 Expected to Advance into Phase 2 Trial for Genital Herpes by End of 2026

THOMSON REUTERS
·
Sep 09

Assembly Biosciences - Gilead Retains Sole Right for Clinical Development and Commercialization of Hsv Hpi Program

THOMSON REUTERS
·
Sep 09

Moderately bullish activity in Moderna with shares down 1.79%

TIPRANKS
·
Sep 09